Introduction
Lp-PLA2 is also known as platelet-activating factor acetylhydrolase (PAF-AH). The molecular weight is 45KDa. It is synthesized and secreted by mature macrophages and lymphocytes, and is regulated by inflammatory mediators. It hydrolyzes the phospholipids of low-density lipoproteins to produce pro-inflammatory substances lysolecithin and oxidized fatty acids, so it has the effect of promoting inflammation and promoting atherosclerosis.
Lp-PLA2 is an independent cardiovascular disease risk predictor and is not affected by other biological indicators. It also provides new evidence for the link between inflammation, atherosclerosis, and cardiovascular disease.[1]
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that plays a role in the inflammation of blood vessels and is thought to help promote atherosclerosis. Biotime rapid quantitative test kit measures the amount or activity of Lp-PLA2 in the human blood.
Advantages
Simple operation and fast response (10min)
Clinical Significance
✔ Markers of vascular endothelial inflammation
✔ Initiated in the early stages of the vascular inflammation process
✔ Not affected by other inflammatory diseases
✔ It is a specific target for drug intervention and treatment of coronary heart disease
Application
ICU, Respiratory Medicine, Cardiology
Reference
1.The Lp-PLA2 Studies Collaboration, Lancet 2010; 375: 1536–44.
